Denmark

As the Danish vaccine maker plots further M&A activity.

Norway’s pharmaceutical industry association says it is waiting to hear from the ministry of health about how it will address the country’s low willingness to pay for innovation.

Nearly 50 medicines are now included in a Nordic pilot that relaxes language requirements on packaging to help improve access to essential hospital treatments.

The Phase III anti-alpha-synuclein antibody has the potential to become a first-in-class therapy for multiple system atrophy.

Standing “shoulder to shoulder” can help alleviate difficult global market conditions, according to the Joint Nordic HTA Body.

In 2026, the Danish inspectors plan to focus on whether drug manufacturing procedures still match the approved marketing dossier, and will require wholesalers to show that the computerized systems used in distribution are fit for purpose.

Adam Steensberg also said that injectables are here to stay in the obesity market even with the arrival of oral Wegovy.

A pivotal year lies ahead for its Roche-partnered obesity hopeful petrelintide.

With the ongoing launch of the chronic hand eczema therapy, and the addition of Spevigo, the Danish group has entered 2026 with strong momentum, its CEO Christophe Bourdon tells Scrip.

The US Most Favored Nation pricing policy that references Danish drug prices is making companies think twice about investing in R&D in the country and risks Denmark’s status as an important “life sciences nation,” according to Lif, the Danish pharmaceutical industry association.

The inflammatory skin disease typically affects the anogenital area and the Denmark-headquartered firm has started a Phase III trial evaluating its chronic hand eczema in that space.

Europe produces world-class science, but lags behind other regions in translating discoveries into groundbreaking innovations that create jobs and drive economic growth. A new fund from the owners of Novo Nordisk hopes to change that.